Amer Sports
AS | NYSE
$29.13
-$0.81 (-2.71%)
At close: Nov 16, 2026, 3:59 PM ET
$29.05
-$0.08 (-0.27%)
After-hours:
Nov 16, 2026, 7:57 PM ET
Amer Sports Company Profile
Company profile explainedCompany Profile
Amer Sports, Inc. is a global enterprise dedicated to the creation, production, promotion, and sale of athletic equipment, clothing, footwear, and related accessories. The company's extensive reach covers Europe, the Middle East, Africa, the Americas, China, and the wider Asia Pacific region. Its operations are structured into three main divisions. The Technical Apparel segment focuses on high-performance outdoor wear, shoes, and accessories, primarily under the Arc'teryx and Peak Performance brands. The Outdoor Performance segment supplies a variety of outdoor apparel, footwear, accessories, and winter sports gear from labels such as Salomon, Atomic, Armada, and ENVE. Finally, the Ball & Racquet Sports segment delivers sports equipment, activewear, and accessories, featuring prominent brands like Wilson, DeMarini, Louisville Slugger, EvoShield, and ATEC. Beyond these brand-specific offerings, Amer Sports' product range includes specialized items like climbing gear, hiking and running shoes, skiing and snowboarding equipment, functional athletic apparel, and lifestyle footwear. They also provide sporting goods for popular activities such as tennis, baseball, American football, basketball, golf, and many other professional and recreational sports. The company's products are distributed through a diverse network that encompasses its own retail stores, major sporting goods retailers, specialty shops, independently operated partner stores, and various distributors. Furthermore, sales are conducted online via their proprietary e-commerce platforms, as well as through retailer-owned and third-party e-commerce sites. Established in 1950 and headquartered in Helsinki, Finland, the company was previously known as Amer Sports Management Holding (Cayman) Limited, officially changing its name to Amer Sports, Inc. in August 2023.
Key Executives
| Name | Position |
|---|---|
| Jie Zheng | Chief Executive Officer & Director |
| Andrew E. Page | Chief Financial Officer |
| Stefan Schubert | Chief Information Officer & Senior Vice President of Group IT |
| Anne Larilahti | Senior Vice President of Sustainability |
| Jutta Karlsson | General Counsel |
| Omar Regis Saad | Senior Vice President of Group Investor Relations & Capital Markets |
| Paivi Antola | Senior Vice President of Communications |
| Sebastian Lund | Chief Human Resources Officer |
| Wen-Chang Chen | Chief Strategy Officer |
| Wolfgang Mayrhofer | President of Atomic & Armada |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | 3 | Filing |
| Oct 16, 2026 | 6-K | Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 16, 2026 | 6-K | Filing |
| Sep 15, 2026 | 144 | Filing |
| Sep 02, 2026 | 4 | Filing |
| Sep 02, 2026 | 144 | Filing |
| Aug 24, 2026 | SC 13D/A | [Amend] Filing |
| Aug 18, 2026 | 6-K | Filing |
| Aug 18, 2026 | 6-K | Filing |
Amer Sports
| Country | Finland |
| IPO Date | Feb 1, 2024 |
| Industry | Leisure |
| Sector | Consumer Cyclical |
| Employees | 15,400 |
| CEO | Jie Zheng |
Contact Details
Siltasaarenkatu 8-10 Helsinki,
UU 00530 Finland
Stock Details
| Ticker Symbol | AS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001988894 |
| CUSIP Number | G0260P102 |
| ISIN Number | KYG0260P1028 |
| SIC Code | 2300 |
Recent News
- 4 days ago / zacks.comBest Health & Fitness Stocks to Buy on Strong Market Potential
- 4 days ago / zacks.comAhead of Amer Sports, Inc. (AS) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
- 6 days ago / zacks.comASO or AS: Which Is the Better Value Stock Right Now?
- 14 days ago / gurufocus.comGE HealthCare reinforces leadership in AI with Lung Guidance and AutoAS on Vscan Air for point of care ultrasound assessments
- 27 days ago / zacks.comASO vs. AS: Which Stock Is the Better Value Option?
- 1 month ago / gurufocus.comSKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
- 1 month ago / fool.comAmer Sports Chief Strategy Officer Exercises Options to Acquire More than $7 Million Shares. Is This a Signal to Buy AS?
- 1 month ago / gurufocus.comNew SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
- 2 months ago / gurufocus.comAbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
- 2 months ago / gurufocus.comAbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
Add to Watchlist
Select watchlists to add or remove AS